1. Home
  2. SGML vs CAPR Comparison

SGML vs CAPR Comparison

Compare SGML & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sigma Lithium Corporation

SGML

Sigma Lithium Corporation

N/A

Current Price

$13.09

Market Cap

1.6B

Sector

Industrials

ML Signal

N/A

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

N/A

Current Price

$33.27

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SGML
CAPR
Founded
2011
2005
Country
Brazil
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2021
2011

Fundamental Metrics

Financial Performance
Metric
SGML
CAPR
Price
$13.09
$33.27
Analyst Decision
Sell
Strong Buy
Analyst Count
2
8
Target Price
$16.75
$41.38
AVG Volume (30 Days)
3.1M
921.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$22,270,465.00
Revenue This Year
$31.30
N/A
Revenue Next Year
$136.50
$17,308.50
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.25
$4.30
52 Week High
$16.88
$40.37

Technical Indicators

Market Signals
Indicator
SGML
CAPR
Relative Strength Index (RSI) 49.26 72.07
Support Level $10.26 $22.09
Resistance Level $16.78 $40.37
Average True Range (ATR) 1.14 1.84
MACD -0.16 0.46
Stochastic Oscillator 26.08 71.58

Price Performance

Historical Comparison
SGML
CAPR

About SGML Sigma Lithium Corporation

Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: